Dermatopathology Report Interpretation

Report Findings - What Each Finding Means

Diagnosis: Lichen Planus (LP)

Differential Diagnosis to Consider Clinically

1. Lichen striatus - linear, self-resolving; correlate with clinical distribution
2. Lichenoid drug eruption - eosinophils are absent here, making this less likely; still review medications (beta-blockers, ACE inhibitors, antimalarials, thiazides, gold, NSAIDs, penicillamine are known culprits)
3. Benign lichenoid keratosis - typically solitary; parakeratosis absent here
4. Graft-vs-host disease (lichenoid) - unlikely given no transplant history implied

Treatment Recommendations

Step 1 - First-Line (Topical, for localized disease)

• Superpotent topical corticosteroids (e.g., clobetasol propionate 0.05% ointment twice daily) - first-line for cutaneous LP; apply under occlusion for thicker/hypertrophic lesions
• Topical calcineurin inhibitors - tacrolimus 0.1% ointment or pimecrolimus 1% cream as steroid-sparing alternatives, especially for sensitive areas (face, genitalia)
• Antihistamines (e.g., cetirizine 10 mg OD or hydroxyzine 25 mg at night) for pruritus control

Step 2 - Second-Line (Widespread or refractory disease)

• Oral corticosteroids - prednisone 0.3-1 mg/kg/day for 4-6 weeks, then taper over 4-6 weeks. Effective for rapid disease control. Always combine with a topical agent; monotherapy is not recommended due to high relapse rate (~32%)
• Sulfasalazine - highest evidence level among steroid-sparing agents; start at 1 g/day, increase by 0.5 g every 3 days to maximum 2.5 g/day. Monitor CBC and LFTs (risk of agranulocytosis). Shows 83% improvement in skin lesions at 6 weeks
• Metronidazole - 250 mg three times daily for 12 weeks (74% response rate at 3 months). Well-suited for generalized cutaneous LP; monitor for peripheral neuropathy
• Hydroxychloroquine - 200-400 mg/day (up to 6.5 mg/kg ideal body weight) for 6-12 months; favorable side effect profile; useful for more chronic/resistant cases

Step 3 - Third-Line (Refractory/severe disease)

• Acitretin (retinoid) - 30 mg/day for 8 weeks; 64% marked improvement in trials; especially effective for hypertrophic LP; monitor lipids and LFTs; teratogenic (caution though she is 54)
• Methotrexate - for ulcerative or refractory disease
• Mycophenolate mofetil (MMF) - for lymphocyte-targeted immunosuppression in refractory disease
• Narrowband UVB or PUVA phototherapy - good evidence for generalized cutaneous LP
• Cyclosporine - third-line due to side effect profile

If Oral Mucosal Involvement is Present

• Topical corticosteroid in Orabase (triamcinolone acetonide 0.1%) or high-potency steroid mouthwash
• Topical tacrolimus 0.1% is equally effective and preferred for long-term use
• Monitor for malignant transformation (oral LP carries ~1% risk of SCC)

Additional Management Points

1. Drug history review - screen for medications that can trigger lichenoid reactions; if a culprit drug is identified, discontinue it
2. Hepatitis C screening - LP has a well-established association with HCV infection; check anti-HCV serology
3. Thyroid disease screening - LP is associated with autoimmune thyroid disease
4. Lichen striatus exclusion - as advised in the report; lichen striatus is self-limiting and requires only reassurance and emollients
5. Follow-up - LP can spontaneously resolve in 1-2 years in most cutaneous cases; chronic/hypertrophic and mucosal disease persists longer
6. Sun protection - particularly for actinic LP variant; general photoprotection is advisable
7. Psychological support - pruritus can significantly impact quality of life

Note: This report interpretation is for educational reference. Clinical management should be individualized by the treating dermatologist (Dr. Shobit Caroli, who referred this case), taking into account the patient's full clinical picture, extent of skin involvement, comorbidities, and current medications.